CRLF2 and acute lymphoblastic leukemia: To validate these in vitro observations, we treated another IGH::CRLF2/JAK2R683G-mutant Ph-like ALL PDX model (luciferase+ ALL121 [19]) with simultaneous ruxolitinib and TSLPRCART.